4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Plasma proteomic signature of the risk of developing mobility disability: A 9‐year follow‐up

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Mobility disability is a powerful indicator of poor health in older adults. The biological and pathophysiological mechanism underlying the development of mobility disability remains unknown. This study conducted a data‐driven discovery phase investigation to identify plasma proteins that predict the incidence of mobility disability in community‐dwelling older adults without mobility disability at baseline.

          Methods

          We investigated 660 women and men, aged 71.9 ± 6.0 (60–94) years, who participated in the Invecchiare in Chianti, “Aging in the Chianti Area” study and completed the 400‐m walk at fast pace (400‐m walk) at enrollment. Median follow‐up time was 8.57 [interquartile, 3.20–9.08] years. SOMAscan technology was used to measure 1,301 plasma proteins at enrollment. The incident of mobility disability was defined as inability to complete the 400‐m walk. Protein‐specific Cox proportional hazard model was adjusted for sex, age, and other important covariates.

          Results

          Plasma levels of 75 proteins predicted mobility disability ( p < .05). Significant proteins were enriched for the KEGG “PI3K‐Akt signaling,” “phagosomes,” and “cytokine–cytokine receptor interaction” pathways. After multiple comparison adjustment, plasma cathepsin S (CTSS; hazard ratio [HR] 1.33, 95% CI: 1.17, 1.51, q = 0.007), growth/differentiation factor 15 (GDF15; HR: 1.45, 95% CI: 1.23, 1.72, q = 0.007), and thrombospondin‐2 (THBS2; HR: 1.44, 95% CI: 1.22, 1.69, q = 0.007) remained significantly associated with high risk of losing mobility.

          Conclusion

          CTSS, GDF15, and THBS2 are novel blood biomarkers associated with new mobility disability in community‐dwelling individuals. Overall, our analysis suggests that cellular senescence and inflammation should be targeted for prevention of mobility disability.

          Abstract

          Among 1,301 plasma proteins assessed, cathepsin S, thrombospondin‐2, and growth/differentiation factor 15 significantly and independently predicted mobility loss in 660 community‐dwelling adults. Proteins associated with mobility loss were enriched for senescence‐associated secretory phenotype and for proteins in the PI3K‐Akt, phagosome, or cytokine–cytokine receptor interaction pathways. High plasma levels of SASP‐induced proteins related to inflammation and phagocytes activation mark a condition of high risk of mobility loss.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A proteomic atlas of senescence-associated secretomes for aging biomarker development

          The senescence-associated secretory phenotype (SASP) has recently emerged as a driver of and promising therapeutic target for multiple age-related conditions, ranging from neurodegeneration to cancer. The complexity of the SASP, typically assessed by a few dozen secreted proteins, has been greatly underestimated, and a small set of factors cannot explain the diverse phenotypes it produces in vivo. Here, we present the “SASP Atlas,” a comprehensive proteomic database of soluble proteins and exosomal cargo SASP factors originating from multiple senescence inducers and cell types. Each profile consists of hundreds of largely distinct proteins but also includes a subset of proteins elevated in all SASPs. Our analyses identify several candidate biomarkers of cellular senescence that overlap with aging markers in human plasma, including Growth/differentiation factor 15 (GDF15), stanniocalcin 1 (STC1), and serine protease inhibitors (SERPINs), which significantly correlated with age in plasma from a human cohort, the Baltimore Longitudinal Study of Aging (BLSA). Our findings will facilitate the identification of proteins characteristic of senescence-associated phenotypes and catalog potential senescence biomarkers to assess the burden, originating stimulus, and tissue of origin of senescent cells in vivo.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Assessment of Variability in the SOMAscan Assay

            SOMAscan is an aptamer-based proteomics assay capable of measuring 1,305 human protein analytes in serum, plasma, and other biological matrices with high sensitivity and specificity. In this work, we present a comprehensive meta-analysis of performance based on multiple serum and plasma runs using the current 1.3 k assay, as well as the previous 1.1 k version. We discuss normalization procedures and examine different strategies to minimize intra- and interplate nuisance effects. We implement a meta-analysis based on calibrator samples to characterize the coefficient of variation and signal-over-background intensity of each protein analyte. By incorporating coefficient of variation estimates into a theoretical model of statistical variability, we also provide a framework to enable rigorous statistical tests of significance in intervention studies and clinical trials, as well as quality control within and across laboratories. Furthermore, we investigate the stability of healthy subject baselines and determine the set of analytes that exhibit biologically stable baselines after technical variability is factored in. This work is accompanied by an interactive web-based tool, an initiative with the potential to become the cornerstone of a regularly updated, high quality repository with data sharing, reproducibility, and reusability as ultimate goals.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation.

              Here we identified growth-differentiation factor 15 (GDF15) (also known as MIC-1), a secreted member of the transforming growth factor (TGF)-beta superfamily, as a novel antihypertrophic regulatory factor in the heart. GDF15 is not expressed in the normal adult heart but is induced in response to conditions that promote hypertrophy and dilated cardiomyopathy. To elucidate the function of GDF15 in the heart, we generated transgenic mice with cardiac-specific overexpression. GDF15 transgenic mice were normal but were partially resistant to pressure overload-induced hypertrophy. Expression of GDF15 in neonatal cardiomyocyte cultures by adenoviral-mediated gene transfer antagonized agonist-induced hypertrophy in vitro. Transient expression of GDF15 outside the heart by intravenous adenoviral delivery, or by direct injection of recombinant GDF15 protein, attenuated ventricular dilation and heart failure in muscle lim protein gene-targeted mice through an endocrine effect. Conversely, examination of Gdf15 gene-targeted mice showed enhanced cardiac hypertrophic growth following pressure overload stimulation. Gdf15 gene-targeted mice also demonstrated a pronounced loss in ventricular performance following only 2 weeks of pressure overload stimulation, whereas wild-type controls maintained function. Mechanistically, GDF15 stimulation promoted activation of SMAD2/3 in cultured neonatal cardiomyocytes. Overexpression of SMAD2 attenuated cardiomyocyte hypertrophy similar to GDF15 treatment, whereas overexpression of the inhibitory SMAD proteins, SMAD6/7, reversed the antihypertrophic effects of GDF15. These results identify GDF15 as a novel autocrine/endocrine factor that antagonizes the hypertrophic response and loss of ventricular performance, possibly through a mechanism involving SMAD proteins.
                Bookmark

                Author and article information

                Contributors
                yusuke.osawa@nih.gov
                FerrucciLu@grc.nia.nih.gov
                Journal
                Aging Cell
                Aging Cell
                10.1111/(ISSN)1474-9726
                ACEL
                Aging Cell
                John Wiley and Sons Inc. (Hoboken )
                1474-9718
                1474-9726
                10 March 2020
                April 2020
                : 19
                : 4 ( doiID: 10.1111/acel.v19.4 )
                : e13132
                Affiliations
                [ 1 ] Longitudinal Study Section Translational Gerontology Branch National Institute on Aging National Institutes of Health Baltimore MD USA
                [ 2 ] Wilmer Eye Institute Johns Hopkins University School of Medicine Baltimore MD USA
                [ 3 ] Clinical Research Core National Institute on Aging National Institutes of Health Baltimore MD USA
                [ 4 ] Laboratory of Human Carcinogenesis Center for Cancer Research National Cancer Institute NIH Bethesda MD USA
                [ 5 ] Precision Immunology, Immunology and Inflammation Research Therapeutic Area Sanofi Cambridge MA USA
                [ 6 ] Geriatric Unit Azienda Sanitaria di Firenze Florence Italy
                Author notes
                [*] [* ] Correspondence

                Yusuke Osawa and Luigi Ferrucci, National Institute on Aging, MedStar Harbor Hospital 5th floor, 3001 S. Hanover Street, Baltimore, MD 21225, USA.

                Emails: yusuke.osawa@ 123456nih.gov (Y. O.); FerrucciLu@ 123456grc.nia.nih.gov (L. F.)

                Author information
                https://orcid.org/0000-0002-7706-5166
                Article
                ACEL13132
                10.1111/acel.13132
                7189986
                32157804
                e8ea8293-1a1e-43f0-b9a5-ac19efe7681d
                © 2020 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 22 November 2019
                : 10 February 2020
                : 18 February 2020
                Page count
                Figures: 1, Tables: 2, Pages: 9, Words: 7428
                Funding
                Funded by: National Institute on Aging , open-funder-registry 10.13039/100000049;
                Award ID: 263MD9164
                Funded by: The National Institutes of Health , open-funder-registry 10.13039/100000009;
                Award ID: R01AG057723
                Award ID: R01AG027012
                Award ID: R01HL111271
                Award ID: R21HL112662
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                April 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.1 mode:remove_FC converted:29.04.2020

                Cell biology
                cathepsin s,growth/differentiation factor 15,mobility disability,proteomics,thrombospondin‐2

                Comments

                Comment on this article